Finding advances search for cure other than liver transplantation
A protein modified to increase the amount of time it circulates in the bloodstream appears to reverse liver fibrosis and cirrhosis in rats, according to results of a study led by Johns Hopkins researchers.
The investigators say the findings, reported ahead of print in the March 3 early view edition of Hepatology, advance the search for a potential cure for the thousands of patients worldwide living with these incurable diseases. At present, there is little effective treatment and no cure other than liver transplantation, which carries its own risks and often fails.
“Our findings demonstrate that the damaging effects of liver cirrhosis in laboratory rats can be effectively treated, and perhaps even reversed, using a protein therapeutic that has been modified to enhance its activity through site-specific conjugation of a polymer that greatly enhances its residence time in the body,” says senior author Justin Hanes, Ph.D., director of the Center for Nanomedicine at the Wilmer Eye Institute at Johns Hopkins. “This approach has tremendous potential to help people with this devastating condition and may also be helpful to the millions of patients with other diseases where fibrosis plays an important role.”
Liver fibrosis and its more severe form, cirrhosis, are caused by scar tissue that forms in the liver that is usually induced by chronic alcohol abuse, infections and autoimmune diseases. The progressive stiffening of the liver, a hallmark of the disorders, occurs when a type of liver cell known as the hepatic stellate cell is “activated” and overproduces the stringy network of proteins called the extracellular matrix that binds cells together.
Being able to turn cirrhosis around, especially in its late stages, would be a great boon, says Seulki Lee, Ph.D., assistant professor in the Department of Radiology and Radiological Science at the Johns Hopkins University School of Medicine. “That’s because liver fibrosis and cirrhosis can be asymptomatic for decades,” Lee says. “Many patients only seek treatment when their disease becomes very advanced, at which point liver transplant is their only option.”
Lee cautions, however, that his team’s work is years from any possible application to patients.
Scientists have known for more than a decade that a protein called tumor necrosis factor-related apoptosis-inducing ligand — TRAIL, for short — can specifically kill activated hepatic stellate cells that overproduce the extracellular matrix, sparing healthy cells in the liver. However, Lee explains, TRAIL has thus far proven unsuccessful for clinical use because in animal studies, enzymes in the bloodstream quickly degrade it before it has time to work.
Seeking a way to extend TRAIL’s half-life, or the time that it remains intact in the bloodstream, Lee and his colleagues coated TRAIL with polyethylene glycol (PEG), a synthetic polymer that’s widely used as a preservative, lubricant and ingredient in skin creams, and is already being used to extend the bloodstream life of a handful of drugs that treat neutropenia, hemophilia and rheumatoid arthritis.
Lee says initial experiments showed that this “PEGylated” TRAIL had a half-life of between eight and nine hours in monkeys, compared to less than 30 minutes for the unmodified protein. When the scientists intravenously dosed rats that had liver fibrosis with the modified TRAIL for 10 days, the animals’ activated hepatic stellate cells died off. By fighting these bad cells, signs of fibrosis began to diminish. Further investigation showed that multiple genes associated with fibrosis had reduced activity, and the proteins produced by these genes faded away.
Findings were similar in rats with advanced cirrhosis, Lee says. Additionally, when the researchers examined the rodents’ liver tissue under a microscope, they found that animals treated with PEGylated TRAIL had fewer deposits of collagen and other extracellular matrix proteins, offering some evidence that the disease had actually been reversed.
Further experiments showed that PEGylated TRAIL selectively killed human-activated hepatic stellate cells growing in petri dishes while leaving normal liver cells unharmed, suggesting that findings in these animal models could apply to damaged human livers with limited toxicity concerns.
Lee says the research team hopes to develop PEGylated TRAIL for clinical trials in human patients in the next two years. He adds that some preliminary data suggest that the modified protein could also treat other fibrotic diseases as well, such as pancreatic or lung fibrosis, which also have no effective treatment.
“Eventually,” Lee says, “we might be able to develop PEGylated TRAIL into a universal anti-fibrotic agent that can treat many different conditions.”
Learn more: Modified protein reverses cirrhosis in lab rats
The Latest on: Protein therapeutic
via Google News
The Latest on: Protein therapeutic
- Peptide Therapeutics Market To Reach USD 50.60 Billion By 2026 | Reports and Dataon March 23, 2020 at 5:33 pm
New York, March 23, 2020 -- The global Peptide Therapeutics market was valued at USD 25.35 billion in 2018 and is expected to reach USD 50.60 billion by the year 2026, at a.
- Design Therapeutics debuts with $45M to tackle degenerative disorderson March 23, 2020 at 7:10 am
San Diego-based Design Therapeutics is taking aim at nucleotide repeat disorders, where a mutation increases the number of times a DNA sequence is repeated. These mutations cause disease in multiple ...
- Stoke Therapeutics Reports Full Year 2019 Financial Results and Provides Business Updateson March 23, 2020 at 5:27 am
--(BUSINESS WIRE)--Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression ...
- NeoImmuneTech Enters into Exclusive License Agreement with Ubix Therapeutics to Develop Drug Candidates Including T Cell Suppressor Blockadeon March 23, 2020 at 4:00 am
--(BUSINESS WIRE)--NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company today announced it has entered into an exclusive license agreement with Ubix Therapeutics, Inc. (UBIX) ...
- Targeted protein degradation: the next wave of therapeuticson March 23, 2020 at 1:39 am
Using the ubiquitin-proteasome system to fight inflammatory conditions could provide more treatment options for patients. Dr Jared Gollob from Kymera Therapeutics explains why targeted protein ...
- Global Plasma Protein Therapeutic Market 2019 Size (value & volume) by Company, Key Regions/Countries, Products and Application 2025on March 20, 2020 at 6:14 am
Global Plasma Protein Therapeutic Market, a new addition to the catalog of Fior Markets, provides an overview of the current state of the market and its evolution. The report contains a forecast of ...
- Therapeutic ACPA inhibits NET formation: a potential therapy for neutrophil-mediated inflammatory diseaseson March 20, 2020 at 5:29 am
Excessive release of neutrophil extracellular traps (NETs) is associated with disease severity and contributes to tissue injury, followed by severe organ damage. Pharmacological or genetic inhibition ...
- Advances in therapeutic peptides targeting G protein-coupled receptorson March 19, 2020 at 1:07 am
have endogenous peptide agonists, and modifying the sequence of these peptides has led to some successful therapeutics. In this Review, Davenport and colleagues discuss strategies to generate ...
- Recombinant Therapeutic Antibodies and Proteins Market- A Novel Approach to Treat Rare and Chronic Diseaseson March 19, 2020 at 12:31 am
Recombinant Therapeutic Antibodies and Proteins Market report provides a thoroughly researched abstract of the key players with considerable shareholdings at a global level regarding demand, sales, ...
- Global plasma protein therapeutics market is expected to grow with a CAGR of 6.1% over the forecast period from 2018-2024on March 12, 2020 at 6:43 pm
New York, March 12, 2020 -- Reportlinker.com announces the release of the report "Plasma Protein Therapeutics Market: Global Industry Analysis, Trends, Market Size, and.
via Bing News